ACE-031 1mg (10 Vials)

ACE-031 is a synthetic protein developed to inhibit myostatin, a natural regulatory protein that limits muscle growth in the human body. Originally created through a collaboration between Acceleron Pharma and Shire Pharmaceuticals, ACE-031 was investigated as a potential treatment for muscle-wasting diseases such as Duchenne Muscular Dystrophy (DMD).

ACE-031 (Ramatercept) is available exclusively for laboratory research purposes. It is not intended for human or veterinary use. Furthermore, researchers must not use this product for diagnostic, therapeutic, or medical applications. Instead, they should handle and store it according to established laboratory safety procedures and scientific best practices.

ACE-031 (Ramatercept) is a recombinant fusion protein developed for laboratory research investigating myostatin inhibition and activin receptor type IIB (ActRIIB) signalling. It acts as a soluble decoy receptor that binds myostatin (GDF-8), activins, and other members of the transforming growth factor-beta (TGF-β) family. As a result, researchers can study the biological pathways that regulate skeletal muscle growth, muscle regeneration, and tissue development.

Manufacturers produce ACE-031 as a high-purity lyophilised protein to support reliable and reproducible laboratory workflows. In addition, every production lot includes a Certificate of Analysis (COA), allowing researchers to verify product identity, purity, and batch consistency. Consequently, ACE-031 remains a valuable research material for studies that require dependable quality and traceability.

Specifications

• Product Name: ACE-031 (Ramatercept)
• Synonyms: Ramatercept, ActRIIB-IgG1 Fc Fusion Protein
• CAS Number: 1621169-52-5
• Quantity: 1 mg Lyophilised Powder
• Form: Recombinant fusion protein
• Purity: ≥95-98% (HPLC verified)
• Documentation: Certificate of Analysis (COA) included with every batch

Research Applications

Researchers commonly use ACE-031 in studies involving:

• Myostatin inhibition
• ActRIIB signalling pathways
• Skeletal muscle biology
• Muscle wasting and sarcopenia models
• Duchenne muscular dystrophy (DMD) research
• TGF-β family protein interactions

Storage & Stability

Store ACE-031 at -20 °C in a dry, desiccated environment for long-term stability. However, researchers may keep the product at 2-8 °C for short-term storage when necessary. Furthermore, avoid repeated freeze-thaw cycles because they may reduce protein integrity and experimental consistency.

Why Choose ACE-031?

• High-purity recombinant fusion protein
• HPLC-verified quality
• COA included with every production lot
• Lyophilised for extended stability
• Excellent batch-to-batch consistency
• Suitable for advanced muscle biology and myostatin research

How ACE-031 Works

ACE-031 is a soluble activin type IIB receptor (ActRIIB) fused to part of a human immunoglobulin (IgG1). It functions by binding to myostatin and related ligands, preventing them from interacting with their natural receptors on muscle cells. By blocking these signals, ACE-031 promotes muscle growth and strength.

Potential Benefits

Although not approved for medical use, ACE-031 has been researched for several potential benefits:

• Increased muscle mass
  By inhibiting myostatin, ACE-031 may promote lean muscle growth, especially in individuals with muscle-wasting conditions.

• Improved strength and endurance
  Clinical trials showed increases in muscle volume and grip strength in some participants.

• Therapeutic use for muscle-related diseases
  It was studied primarily for conditions like Duchenne Muscular Dystrophy (DMD) and sarcopenia (age-related muscle loss).

• Possible use in metabolic health
  Some studies suggested potential benefits in regulating fat mass and improving metabolic profiles.

Research and Clinical Trials

• In early-stage clinical trials, ACE-031 showed promising results in increasing lean body mass and muscle strength in patients with DMD.

• However, clinical development was discontinued in 2011 due to safety concerns and unexpected side effects, including minor bleeding and vascular abnormalities.

• Despite this, research into myostatin inhibition continues, with newer compounds being investigated.

Risks and Side Effects

While ACE-031 is not approved or widely available for therapeutic use, reported side effects during clinical studies included:

• Nosebleeds

• Gum bleeding

• Telangiectasia (small dilated blood vessels)

• Vascular issues

• Unknown long-term effects

These issues led to the suspension of its development.

ACE-031 in Bodybuilding (Off-Label Use)

Due to its muscle-building potential, ACE-031 has attracted attention in the bodybuilding and performance-enhancing communities. However:

• It is not legal for human consumption or sale as a supplement.

• Use is not regulated, and quality control of underground sources is questionable.

• Health risks are significant, particularly with improper dosing or prolonged use.